DICE Therapeutics, Inc. (DICE) Income Statement Analysis

See more : SQLI SA (SQI.PA) Income Statement Analysis – Financial Results

Complete financial analysis of DICE Therapeutics, Inc. (DICE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of DICE Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Canopy Finance Limited (CANOPYFIN.BO) Income Statement Analysis – Financial Results
MSCI EMU DEFENSIVE SECT NETR EU (RFLL.BO) Income Statement Analysis – Financial Results
TG Therapeutics, Inc. (TGTX) Income Statement Analysis – Financial Results
U.S. Bancorp (USB-PQ) Income Statement Analysis – Financial Results
AIRA Factoring Public Company Limited (AF.BK) Income Statement Analysis – Financial Results

DICE Therapeutics, Inc. (DICE)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.dicemolecules.com

About DICE Therapeutics, Inc.

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 integrin for the treatment of idiopathic pulmonary fibrosis. In addition, the company focuses on immuno-oncology for antibody therapeutics. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Metric	2022	2021	2020	2019
Revenue	0.00	1.13M	863.00K	5.78M
Cost of Revenue	0.00	0.00	0.00	0.00
Gross Profit	0.00	1.13M	863.00K	5.78M
Gross Profit Ratio	0.00%	100.00%	100.00%	100.00%
Research & Development	62.56M	36.51M	19.58M	15.72M
General & Administrative	25.66M	12.22M	5.00M	3.61M
Selling & Marketing	0.00	0.00	0.00	0.00
SG&A	25.66M	12.22M	5.00M	3.61M
Other Expenses	0.00	0.00	0.00	0.00
Operating Expenses	88.22M	48.73M	24.58M	19.32M
Cost & Expenses	88.22M	48.73M	24.58M	19.32M
Interest Income	5.21M	136.00K	139.00K	635.00K
Interest Expense	679.00K	174.00K	13.00K	26.00K
Depreciation & Amortization	5.21M	136.00K	836.00K	1.34M
EBITDA	-83.01M	-47.47M	-22.89M	-12.21M
EBITDA Ratio	0.00%	-4,219.29%	-2,651.80%	-211.36%
Operating Income	-88.22M	-47.60M	-23.72M	-13.55M
Operating Income Ratio	0.00%	-4,231.38%	-2,748.67%	-234.58%
Total Other Income/Expenses	4.33M	-1.36M	-18.00K	609.00K
Income Before Tax	-83.89M	-48.96M	-23.74M	-12.94M
Income Before Tax Ratio	0.00%	-4,351.91%	-2,750.75%	-224.03%
Income Tax Expense	-2.22M	-487.00K	13.00K	26.00K
Net Income	-81.66M	-48.47M	-23.75M	-12.96M
Net Income Ratio	0.00%	-4,308.62%	-2,752.26%	-224.48%
EPS	-2.07	-3.91	-1.02	-0.56
EPS Diluted	-2.07	-3.91	-1.02	-0.56
Weighted Avg Shares Out	39.40M	12.38M	23.23M	23.23M
Weighted Avg Shares Out (Dil)	39.40M	12.38M	23.23M	23.23M

Lilly Completes Acquisition of DICE Therapeutics

August 9, 2023prnewswire.com

INDIANAPOLIS , Aug. 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE). The acquisition expands Lilly's immunology portfolio to include DICE's novel oral therapeutic candidates, including...

Lilly Announces Extension of Tender Offer to Acquire DICE

July 25, 2023prnewswire.com

INDIANAPOLIS , July 25, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of DICE Therapeutics,...

Drugmakers' deal making will plow ahead despite antitrust scrutiny, analysts say

July 12, 2023marketwatch.com

The brisk pace of biopharmaceutical deal making seen in the first half of this year may only accelerate in the months ahead, even as regulators take a hard look at some of the bigger deals, analysts say.

DICE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of DICE Therapeutics, Inc. - DICE

July 10, 2023businesswire.com

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of DICE Therapeutics, Inc. (NasdaqGM: DICE) to Eli Lilly and Company (NYSE:...

DICE Therapeutics (DICE) Up 37% on Buyout Offer from Eli Lilly

June 21, 2023zacks.com

DICE Therapeutics (DICE) is set to be acquired by pharma-giant Eli Lilly (LLY) in an all-cash transaction for $2.4 billion. The transaction will likely close by third-quarter 2023.

ETFs to Capitalize on Eli Lilly's Buyout of DICE Therapeutics

June 21, 2023zacks.com

Eli Lilly (LLY) has agreed to acquire DICE Therapeutics (DICE) in a cash deal worth approximately $2.4 billion. This strategic move is part of Eli Lilly's efforts to bolster its immunology pipeline, specifically targeting immune disease-related treatments.

Eli Lilly takeover of DICE Therapeutics ‘makes strategic sense,' says broker

June 21, 2023proactiveinvestors.com

Eli Lilly and Co (NYSE:LLY)'s $2.4 billion acquisition of DICE Therapeutics “makes strategic sense,” bolstering the global pharmaceutical company's presence in immunology, analysts at UBS said in a note on Wednesday. UBS, which has a ‘Buy' rating and a 12-month...